EA200001015A1 - Способы увеличения прочности и упругости кости и сокращения переломов - Google Patents

Способы увеличения прочности и упругости кости и сокращения переломов

Info

Publication number
EA200001015A1
EA200001015A1 EA200001015A EA200001015A EA200001015A1 EA 200001015 A1 EA200001015 A1 EA 200001015A1 EA 200001015 A EA200001015 A EA 200001015A EA 200001015 A EA200001015 A EA 200001015A EA 200001015 A1 EA200001015 A1 EA 200001015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fractures
elasticity
bone
reduce
incidence
Prior art date
Application number
EA200001015A
Other languages
English (en)
Other versions
EA003362B1 (ru
Inventor
Джэнет М. Хок
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200001015(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200001015A1 publication Critical patent/EA200001015A1/ru
Publication of EA003362B1 publication Critical patent/EA003362B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к способу для увеличения прочности и/или упругости костей и/или снижения вероятности и/или тяжести переломов костей с помощью введения паратиреоидного гормона. Способ может быть использован для увеличения прочности или упругости костной ткани в области возможной или реальной травмы, такой как травма верхней части бедренной кости или позвоночника у пациента с риском остеопороза или страдающего остеопорозом. Способ по настоящему изобретению может уменьшить распространенность переломов позвоночника, уменьшить распространенность множественных переломов позвоночника, уменьшить тяжесть переломов позвоночника и/или уменьшить распространенность не связанных с позвоночником переломов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001015A 1998-08-19 1999-08-19 Способ увеличения прочности и упругости кости и сокращения переломов EA003362B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Publications (2)

Publication Number Publication Date
EA200001015A1 true EA200001015A1 (ru) 2001-02-26
EA003362B1 EA003362B1 (ru) 2003-04-24

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001015A EA003362B1 (ru) 1998-08-19 1999-08-19 Способ увеличения прочности и упругости кости и сокращения переломов

Country Status (33)

Country Link
US (2) US6977077B1 (ru)
EP (3) EP2907522B1 (ru)
JP (5) JP2002523375A (ru)
KR (1) KR100454207B1 (ru)
CN (1) CN1205997C (ru)
AR (1) AR033639A1 (ru)
AT (1) ATE231000T1 (ru)
AU (1) AU746277B2 (ru)
BR (1) BR9909445A (ru)
CA (1) CA2325371C (ru)
CO (1) CO5130020A1 (ru)
CY (2) CY1113343T1 (ru)
CZ (1) CZ301017B6 (ru)
DE (2) DE69904918T2 (ru)
DK (4) DK1769804T3 (ru)
DZ (1) DZ2873A1 (ru)
EA (1) EA003362B1 (ru)
ES (4) ES2190244T3 (ru)
HK (3) HK1030545A1 (ru)
HR (1) HRP20000755A2 (ru)
HU (2) HU1200430D0 (ru)
ID (1) ID29039A (ru)
IL (2) IL138829A0 (ru)
MY (1) MY129227A (ru)
NO (2) NO323984B1 (ru)
NZ (1) NZ507056A (ru)
PE (1) PE20001089A1 (ru)
PL (1) PL201688B1 (ru)
PT (4) PT2266598T (ru)
TR (1) TR200003455T2 (ru)
TW (1) TW576747B (ru)
UA (1) UA72205C2 (ru)
WO (1) WO2000010596A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CA2539357A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
CA2566032A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
CA2608016A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
ATE543520T1 (de) 2007-04-13 2012-02-15 Kuros Biosurgery Ag Polymergewebeversiegelung
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
EP2217260B1 (en) * 2007-12-04 2016-11-09 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
JP2012512812A (ja) 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
CA2772656A1 (en) 2009-09-09 2011-03-17 Asahi Kasei Pharma Corporation Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
US20140088014A1 (en) 2011-06-07 2014-03-27 Asahi Kasei Pharma Corporation Freeze-dried preparation containing high-purity pth and method for producing same
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US11492386B2 (en) 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
ES2197212T3 (es) * 1994-12-22 2004-01-01 Astrazeneca Ab Preparacion terapeutica para inhalacion que contiene la hormona paratiroidea, pth.
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
EP1005359B1 (en) * 1997-09-09 2005-06-15 F. Hoffmann-La Roche Ag FRACTURE HEALING USING PTHrP ANALOGS
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
JP2015028065A (ja) 2015-02-12
EP2907522B1 (en) 2017-08-02
PT2907522T (pt) 2017-10-23
CA2325371A1 (en) 2000-03-02
KR20010072763A (ko) 2001-07-31
DK1059933T3 (da) 2003-04-07
DE69904918T2 (de) 2003-11-13
BR9909445A (pt) 2000-12-12
IL138829A (en) 2011-01-31
NO20005947L (no) 2000-11-24
HK1102496A1 (en) 2007-11-23
HRP20000755A2 (en) 2001-02-28
NO323984B1 (no) 2007-07-30
CY1113343T1 (el) 2016-06-22
US6977077B1 (en) 2005-12-20
AU5575099A (en) 2000-03-14
HK1212602A1 (zh) 2016-06-17
DK2907522T3 (en) 2017-10-23
CY1119552T1 (el) 2018-03-07
NZ507056A (en) 2003-10-31
MY129227A (en) 2007-03-30
ES2190244T3 (es) 2003-07-16
NO20072983L (no) 2000-11-24
DK2266598T3 (en) 2017-05-15
TW576747B (en) 2004-02-21
AR033639A1 (es) 2004-01-07
EP1059933A1 (en) 2000-12-20
HUP0101594A2 (hu) 2001-11-28
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
EP2266598B1 (en) 2017-02-22
PT2266598T (pt) 2017-05-02
NO20005947D0 (no) 2000-11-24
DE15152726T1 (de) 2015-12-10
ES2549551T3 (es) 2017-11-27
KR100454207B1 (ko) 2004-10-26
ES2621653T3 (es) 2017-07-04
WO2000010596A1 (en) 2000-03-02
JP6177718B2 (ja) 2017-08-09
CZ20004134A3 (cs) 2001-08-15
US7163684B2 (en) 2007-01-16
CZ301017B6 (cs) 2009-10-14
TR200003455T2 (tr) 2001-06-21
UA72205C2 (ru) 2005-02-15
EP2907522A1 (en) 2015-08-19
CN1205997C (zh) 2005-06-15
DK2907522T1 (da) 2015-10-19
ES2549551T1 (es) 2015-10-29
EA003362B1 (ru) 2003-04-24
HU230697B1 (hu) 2017-09-28
PL201688B1 (pl) 2009-04-30
PE20001089A1 (es) 2000-11-04
JP2014139220A (ja) 2014-07-31
HK1030545A1 (en) 2001-05-11
ID29039A (id) 2001-07-26
IL138829A0 (en) 2001-10-31
DZ2873A1 (fr) 2003-12-15
PT1769804E (pt) 2012-11-13
EP2266598A1 (en) 2010-12-29
CN1308545A (zh) 2001-08-15
DE69904918D1 (de) 2003-02-20
ES2393200T3 (es) 2012-12-19
PL343595A1 (en) 2001-08-27
CO5130020A1 (es) 2002-02-27
EP1059933B1 (en) 2003-01-15
ATE231000T1 (de) 2003-02-15
PT1059933E (pt) 2003-06-30
JP2017190332A (ja) 2017-10-19
JP2011021035A (ja) 2011-02-03
US20050197294A1 (en) 2005-09-08
CA2325371C (en) 2004-08-17
DK1769804T3 (da) 2012-10-15
HUP0101594A3 (en) 2002-01-28
HU1200430D0 (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
EA200001015A1 (ru) Способы увеличения прочности и упругости кости и сокращения переломов
Helfet et al. Intraarticular" pilon" fracture of the tibia.
PT1663037E (pt) Montagem de implante ortopédico e de parafuso do osso
ATE255367T1 (de) Marknagelsystem zur frakturheilung bzw. knochenverlängerung
Crowley et al. Femoral diaphyseal aseptic non-unions: is there an ideal method of treatment?
Dy et al. Distal radius fractures: strategic alternatives to volar plate fixation
Sringari et al. Role of valgus osteotomy and fixation by double-angle blade plate in neglected displaced intracapsular fracture of neck of femur in younger patients
Böhler et al. Loss of correction after lateral closing wedge high tibial osteotomy–a human cadaver study
Alho Mineral and mechanics of bone fragility fractures: A review of fixation methods
Singh et al. Unstable recent intracapsular femoral neck fractures in young adults: osteosynthesis and primary valgus osteotomy using broad dynamic compression plate
Shashidhara et al. A prospective study of surgical management of distal end radius fractures using volar rim variable angle locking plates
Kenganal Functional Outcome Of Metaphyseal And Diaphyseal Fractures Of Tibia Treated With Expert Tibial Interlocking Nail-A Prospective Study
Hatab et al. Lessons learned using screws and cable in patellar fractures
Owusu et al. Revision of failed distal interphalangeal arthrodesis complicated by retained headless screw
Robins et al. Customized hook plates for metaphyseal fractures, nonunions and osteotomies in the dog and cat
Whiteside Trochanteric repair and reconstruction in revision total hip arthroplasty
Kovalchuk et al. Our Experience in Using the Ukrndito Polifunctional Apparatus in the Treatment of Long Bone Fractures
AALAMI et al. Treatment of the nonunion of the femoral neck by Valgus osteotomy
George et al. Forearm Fractures
EP1295605A3 (en) Method of increasing bone toughness and stiffness and reducing fractures
SU976970A1 (ru) Способ артродеза тазобедренного сустава
MD2630G2 (ru) Метод остеосинтеза при перипротезных переломах диафиза бедренной кости
SU1421326A1 (ru) Способ устранени деформации проксимального отдела бедра
RU2556788C2 (ru) Способ выполнения периацетабулярной тройной остеотомии таза у подростков
SU1192799A1 (ru) Способ пластики крыши вертлужной впадины

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD

MH4A Revocation of a eurasian patent in part

Designated state(s): RU

ND4A Extension of term of a eurasian patent
MK4A Patent expired

Designated state(s): AM RU

MK4A Patent expired

Designated state(s): KZ